English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, January 4, 2023
四環醫藥(0460.HK):惠升生物成功完成A +輪融資,加速糖尿病及併發症領域佈局
Sihuan Pharmaceutical (0460.HK): Huisheng Biopharmaceutical Successfully Completes A+ Round of Financing, Accelerating the Layout of Diabetes and Complications
Tuesday, August 16, 2022
ADC研發浪潮席捲下,四環醫藥(0460.HK)差異化佈局創新
ADC研发浪潮席卷下,四环医药(0460.HK)差异化布局创新
Wednesday, August 11, 2021
四环医药 (0460.HK):响应医美专项整治,倡导中国医美“正能量”
四環醫藥 (0460.HK):響應醫美專項整治,倡導中國醫美「正能量」
Sihuan Pharmaceutical (0460.HK): Respond to the special directives to combat illegal medical aesthetics services, Advocate 'Positive Energy' in China's Medical Aesthetics Industry
Monday, March 22, 2021
手握多款重磅品种,四环医药跨入“医药+医美”大时代
手握多款重磅品種,四環醫藥跨入「醫藥+醫美」大時代
Thursday, August 27, 2020
四环医药推出股权激励计划,注入公司成长新动力

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575